Use of At-Home COVID-19 Tests - United States, August 23, 2021-March 12, 2022.

COVID-19 testing provides information regarding exposure and transmission risks, guides preventative measures (e.g., if and when to start and end isolation and quarantine), identifies opportunities for appropriate treatments, and helps assess disease prevalence (1). At-home rapid COVID-19 antigen tests (at-home tests) are a convenient and accessible alternative to laboratory-based diagnostic nucleic acid amplification tests (NAATs) for SARS-CoV-2, the virus that causes COVID-19 (2-4). With the emergence of the SARS-CoV-2 B.1.617.2 (Delta) and B.1.1.529 (Omicron) variants in 2021, demand for at-home tests increased† (5). At-home tests are commonly used for school- or employer-mandated testing and for confirmation of SARS-CoV-2 infection in a COVID-19-like illness or following exposure (6). Mandated COVID-19 reporting requirements omit at-home tests, and there are no standard processes for test takers or manufacturers to share results with appropriate health officials (2). Therefore, with increased COVID-19 at-home test use, laboratory-based reporting systems might increasingly underreport the actual incidence of infection. Data from a cross-sectional, nonprobability-based online survey (August 23, 2021-March 12, 2022) of U.S. adults aged ≥18 years were used to estimate self-reported at-home test use over time, and by demographic characteristics, geography, symptoms/syndromes, and reasons for testing. From the Delta-predominant period (August 23-December 11, 2021) to the Omicron-predominant period (December 19, 2021-March 12, 2022)§ (7), at-home test use among respondents with self-reported COVID-19-like illness¶ more than tripled from 5.7% to 20.1%. The two most commonly reported reasons for testing among persons who used an at-home test were COVID-19 exposure (39.4%) and COVID-19-like symptoms (28.9%). At-home test use differed by race (e.g., self-identified as White [5.9%] versus self-identified as Black [2.8%]), age (adults aged 30-39 years [6.4%] versus adults aged ≥75 years [3.6%]), household income (>$150,000 [9.5%] versus $50,000-$74,999 [4.7%]), education (postgraduate degree [8.4%] versus high school or less [3.5%]), and geography (New England division [9.6%] versus West South Central division [3.7%]). COVID-19 testing, including at-home tests, along with prevention measures, such as quarantine and isolation when warranted, wearing a well-fitted mask when recommended after a positive test or known exposure, and staying up to date with vaccination,** can help reduce the spread of COVID-19. Further, providing reliable and low-cost or free at-home test kits to underserved populations with otherwise limited access to COVID-19 testing could assist with continued prevention efforts.

Meat from gene-edited pigs could hit the market.

United States and other countries may soon approve virus-proof pigs.

Skin side effects stymie advance of HIV vaccine.

Strategy of using multiple mRNA shots to hone powerful antibodies hits a pothole.

Covid's cold cousins.

Four largely ignored coronaviruses circulate in humans without causing great harm and may portend the future for SARS-CoV-2.

'I'm not Tony': Anthony Fauci's heir vows new direction at NIAID.

Jeanne Marrazzo, an HIV prevention researcher, sees need for more "holistic" approach to community health problems.

Rifts over equity imperil WHO's pandemic treaty.

As deadline nears, negotiations continue over sharing pathogen sequences and vaccine doses.

Africa may lead rollout of long-lasting HIV drug.

U.S. agency plans to make inexpensive prevention shots widely available for people at risk.

Deadlier strain of mpox spreads to multiple African countries.

Massive outbreak of virus in the Democratic Republic of the Congo spills into neighbors.

Fire-against-fire HIV therapy passes key test in monkeys.

A stripped-down HIV genome can interfere with normal virus replication.

Can 'cow flu' be eliminated-or is it too late?

Feeble government response and lack of industry cooperation hamper U.S. control efforts.

COVID-19 is surging again-with far fewer serious cases.

New variants that elude immunity have caused a massive summer wave.

U.S. government in hot seat for cow flu outbreak response.

Veterinarians and researchers say it has taken too long to share data on viral changes, spread, and milk safety.

Plans to expand African vaccine production face steep hurdles.

Moderna's pause on Kenya project highlights difficulties in creating a competitive vaccine sector on the continent.

A bird flu vaccine for cows? It's complicated.

Market uncertainties, safety rules, and export worries stand in way of H5N1 shots for cattle.

Global pandemic treaty stalls, again, over equity concerns.

But negotiators approve new "pandemic emergency" alarm.

Africa steps up battle against mpox outbreaks.

Research consortium announced as new variant spreads in Congolese mining region.

Virus gone wild.

An ambitious U.S. project aims to sample more than 50 animal species to clarify how the COVID-19 virus moves between people and wildlife.

Worries about bird flu in U.S. cattle intensify.

Farm worker becomes infected as H5N1 appears to spread between dairy cows in five states.

A new force emerges in genomics.

With vision and a big personality, Christian Happi has built a world-class genomics center so Africans can help Africa.

Pulling back the curtain.

Mpox circulated in Nigeria for 8 years before it sparked a global outbreak. Could it have been stopped?